Search clinical trials for: Sorafenib 200mg

Total 2739 results

University of Erlangen-Nürnberg Medical School

Terminated

Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

Germany
Bayer

Completed

Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib (OPTIMIS)

Carcinoma, Hepatocellular

Japan, Turkey, Austria, Czechia, Hungary, Israel, Russian Federation, Slovakia, Switzerland, India, Korea, Republic of, France, Mexico, Indonesia, Singapore, Thailand, Canada, Greece, Netherlands, Spain, Taiwan, Poland, Brazil, China, D... and more
Chong Kun Dang Pharmaceutical

Completed

A Study to Compare PK, PD and Safety of CKD-381 in Healthy Subjects

GERD

Korea, Republic of
Castleton University

Withdrawn

Cannabidiol Effects on Cardiovascular System and Exercise Responses

Healthy

United States
Second Affiliated Hospital of Guangzhou Medical...

Completed

TACE Combined With Sorafenib and Tislelizumab for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Chang Gung Memorial Hospital

Unknown

Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma

Hepatocellular Carcinoma

Taiwan
Bayer

Completed

Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma (SANE)

Carcinoma, Renal Cell

Russian Federation
University of Kansas Medical Center
Bayer

Completed

Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer

Renal Cell Cancer

United States
Jennerex Biotherapeutics

Completed

A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Korea, Republic of
Bayer

Completed

Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin

Cancer

Canada
Indiana University School of Medicine

Completed

Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs

Cataract

United States
Fortune Pharmacal Co., Ltd.
Chinese University of Hong Kong

Completed

Clinical Bioequivalence Study on Two Paracetamol Tablet Formulations

Healthy

Hong Kong
Bayer

Withdrawn

Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer (POWER-NEXT)

Carcinoma, Renal Cell
Bayer

Completed

Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)

Carcinoma, Hepatocellular

Korea, Republic of, Japan
Suzhou Zanrong Pharma Limited

Recruiting

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors

Advanced Solid Tumors | HER2-positive Breast Cancer

United States
Hope Medicine (Nanjing) Co., Ltd

Recruiting

A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia

Androgenetic Alopecia

China
South China Center For Innovative Pharmaceuticals
Xiangya Hospital of Central South University

Completed

The Effect of High Fat Diet on the Pharmacokinetics of AD16 Tablets in Healthy Chinese Adult Subjects

Alzheimer Disease

China
Proacta, Incorporated

Terminated

Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States, Taiwan, Singapore, Hong Kong
Anji Pharma
Covance

Completed

A Proof of Concept Study of Pradigastat in Patients With Functional Constipation

Functional Constipation

China, United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma (HCC)

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Threshold Pharmaceuticals

Completed

Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery

Kidney Cancer | Liver Cancer

United States
Bayer

Terminated

Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy

Carcinoma, Renal Cell
Medical University of South Carolina
Novartis Pharmaceuticals

Completed

Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers

Soft Tissue Sarcoma | Renal Cancer | Non Small Cell Lung Cancer (NSCLC)

United States
Human Genome Sciences Inc., a GSK Company
GlaxoSmithKline

Completed

A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States
Free University Medical Center

Unknown

Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Netherlands
Allist Pharmaceuticals, Inc.

Recruiting

Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation (FAVOUR)

NSCLC

China
Allist Pharmaceuticals, Inc.

Withdrawn

Phase Ib Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation

NSCLC

China
Bayer

Completed

A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (SHARP)

Carcinoma, Hepatocellular

Belgium, Italy, Spain, Canada, Switzerland, Germany, Greece, Russian Federation, France, United States, United Kingdom, Chile, New Zealand, Australia, Romania, Bulgaria, Croatia, Israel, Peru, Poland, Mexico, Brazil, Argentina
Clavis Pharma

Completed

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

Malignant Melanoma

United States, Sweden, Norway
Gary E. Ruoff, M.D.
GlaxoSmithKline

Completed

Comparison of Treximet & Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache

Migraine

United States
Hospital de Clinicas de Porto Alegre

Unknown

Iron Supplementation in Heart Failure Patients With Anemia: The IRON-HF Study

Heart Failure | Anemia

Brazil
First Affiliated Hospital of Zhejiang University

Recruiting

SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT

Unresectable Hepatocellular Carcinoma | Portal Vein Thrombosis

China
University Hospital, Caen

Completed

Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination (O-Mel-Sora)

Uveal Melanoma

France
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States, Italy
Hanlim Pharm. Co., Ltd.

Completed

A Multicenter, Randomized, Double-blind, Parallel Group Study to Determine the Optimal Dose of HL301 After 7 Days Oral Administration in Acute Bronchitis or Acute Exacerbations of Chronic Bronchitis Patients (HL301: Mixed Extract of Rehmannia Glutinosa, Schisandra and so on) (HL301)

Acute Exacerbations of Chronic Bronchitis | Acute Bronchitis

Korea, Republic of
University of KwaZulu
Medical Research Council, South Africa; Centre for the AIDS Programme of Research...

Completed

Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women (PrEP)

HIV-1-infection

South Africa
Kenneth H. Mayer, MD
Gilead Sciences

Completed

HIV Non-Occupational Post-Exposure Prophylaxis (QUAD)

Human Immunodeficiency Virus

United States
Niguarda Hospital

Completed

Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells

Leukemia, Myeloid, Chronic-Phase

Italy
CTI BioPharma
SGS S.A.

Completed

Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects

Myelofibrosis

Moldova, Republic of, Germany
MedDay Pharmaceuticals SA

Unknown

Effect of MD1003 in Spinal Progressive Multiple Sclerosis (MS-SPI)

Multiple Sclerosis

France
Newsoara Biopharma Co., Ltd.

Recruiting

Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects

T2DM (Type 2 Diabetes Mellitus)

China
Medicines for Malaria Venture
Q-Pharm Pty Limited

Terminated

MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants

Malaria, Falciparum

Australia
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis

Desmoid Fibromatosis

United States, Canada
Henan Cancer Hospital
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Esophageal Carcinoma | Lung Cancer, Nonsmall Cell

China
Fundacion SEIMC-GESIDA

Active, not recruiting

Phase IV, a Clinical Trial to Assess Safety and Convenience of the Change From DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control and Neuropsychiatric Vulnerabilities (MIND)

HIV Infections

Spain
Yooyoung Pharmaceutical Co., Ltd.
CliPS Co., Ltd

Completed

Clinical Trial of YYC301 for Treatment of Osteoarthritis of the Knee

Osteoarthritis, Knee

Korea, Republic of
Jonsson Comprehensive Cancer Center

Terminated

Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery

Sarcoma

United States
Ministry of Health, Labour and Welfare, Japan

Unknown

Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC

Neoplasms | Carcinoma | Carcinoma, Hepatocellular | Liver Neoplasms | Advanced Hepatocellular Carcinoma

Japan
Sichuan Cancer Hospital and Research Institute

Recruiting

TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC

Liver Diseases | Digestive System Neoplasms | Liver Neoplasms | Hepatocellular Carcinoma | Antineoplastic Agents | Molecular Mechanisms of Pharmacological Action | Protein Kinase Inhibitors | Sorafenib

China
University Hospital, Bordeaux

Completed

Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma (ACTES)

Hepatocellular Carcinoma (HCC)

France

3

Subscribe